CNBC Wall Street's top stock picks for 2026: Mizuho’s under-the-radar name that could more than triple in value
Based on its 12-month price target, Mizuho sees shares of Vaxcyte soaring almost 300% from current levels.
Based on its 12-month price target, Mizuho sees shares of Vaxcyte soaring almost 300% from current levels.